-
-
-
-
BAFF-R CAR-T: CR 100%
CAR-T
PeproMene Bio's BAFF-R targeted CAR-T therapy PMB-CT01 shows 100% complete response in Phase 1 trials for B-cell lymphomas and leukemia, offering promising, durable results with manageable safety.
-
-
Stylus Medicine Raises $85 Million!
Eli Lilly
Stylus Medicine raises $85M to develop in vivo CAR-T cell therapies, targeting gene insertion, non-viral DNA delivery, and cell therapy solutions with backing from Eli Lilly, Johnson & Johnson, and others.
-
-
2024 Global CAR-T Sales Performance
CAR-T
Discover the sales performance of CAR-T therapies in 2024, including Kymriah, Yescarta, Breyanzi, and more. Explore trends, growth, and challenges in the CAR-T cell therapy market across the US and beyond.
-
In Vivo CAR-T: A New Horizon
CAR-T
Explore the promising future of in vivo CAR-T therapy, a breakthrough in cancer and autoimmune disease treatment. Companies like Interius and Umoja are leading the way with innovative in vivo CAR-T therapies targeting CD19, CD20, and CD22. Discover the latest advances and clinical trials.
嫩江县|
太仆寺旗|
桓仁|
梓潼县|
舞钢市|
秦皇岛市|
湘潭市|
鸡泽县|
儋州市|
四子王旗|
阿拉尔市|
绥宁县|
车致|
开封市|
深水埗区|
昌乐县|
英吉沙县|
丰城市|
中江县|
莎车县|
五常市|
内黄县|
忻城县|
青铜峡市|
新泰市|
县级市|
广平县|
和龙市|
兴仁县|
黔江区|
青田县|
钦州市|
灵台县|
灵武市|
岢岚县|
望江县|
东明县|
赣州市|
松溪县|
崇义县|
章丘市|